Read Time:7 Second
CNBC spoke with 11 current and former Pfizer employees, who asked to remain anonymous, about Pfizer’s dizzying climb, rapid decline and turnaround strategy.
Happy
0 %
Sad
0 %
Excited
0 %
Sleepy
0 %
Angry
0 %
Surprise
0 %
0
0
